OTHER GROUP COMPANIES
market

Supriya Lifescience appoints Rajeev Kumar Jain as Chief Executive Officer & KMP

He has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a "Safety First, Quality Must and EBIDTA Growth" mindset.

October 03, 2022 3:24 IST | India Infoline News Service
Supriya Lifescience Ltd has announced appointment of Rajeev Kumar Jain as Chief Executive Officer (CEO) & Key Managerial Personnel (KMP) w.e.f. October 3, 2022.

Rajeev Jain is a Master of Business Administration (Marketing) from Jivaji University, Gwalior and B Sc (PCB) with distinction. Additionally, he has taken part in business seminars and workshops on corporate transformation in China, Germany, and the Netherlands.

He has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a "Safety First, Quality Must and EBIDTA Growth" mindset.

He is very skilled and experienced in managing regulations and guidelines, such as those from the USFDA, KFDA, EMA, ANVISA, CDSCO, ISO, PMDA, and IDL CHINA.

Throughout his career, he has maintained an impeccable record with reputable companies like Morepen Labs Ltd., Ind Swift Labs, Arch Pharma, Trident Group, Max India (DSM), etc.

He has strategic leadership attributes with a global mindset and has demonstrated lead for cross functional teams with end-to-end solutions & managing optimal utilization of Men, Machine & Material.

Rajiv is the right leader for Supriya Lifescience limited," said Dr. Satish Wagh, Chairman & Managing Director. Rajiv's extensive pharma background and shopfloor skills should help Supriya strengthen manufacturing excellence, develop strategic alliances and expand our international sales presence. We believe his strong leadership experience will help take Supriya to the next level of growth."

"I am very excited to be joining the Supriya team," said Rajiv Kumar Jain. "I believe Supriya has a great business model and talented management team that uniquely positions it to capitalize on the changing Pharmaceutical environment. As the industry evolves, I believe Supriya is in a position to reach newer heights with backward integration, focus on R&D, increasing capacity, and capitalizing on CMO/CDMO potential. Our endeavor would be to achieve healthy revenue growth with healthy margins and upgrade to the evolving GMP and EHS standards."

At around 3:11 PM, Supriya Lifescience Ltd is currently trading at Rs301 per share up by Rs1.05 or 0.35% from its previous closing of Rs299.95 per share on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com

Invest wise with Expert advice

FEATURED ARTICLE

BLOGS

Open Demat Account

Invest wise with Expert advice

By continuing, I accept the Terms & Conditions and agree to receive updates on Whatsapp